Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$67.98

-8.01 (-10.54%)

, BIIB

Biogen

$305.93

-12.18 (-3.83%)

16:07
11/23/16
11/23
16:07
11/23/16
16:07

On The Fly: Top stock stories for Wednesday

Stocks drifted for most of the session after the Dow, S&P and Nasdaq all reached new highs yesterday. The volume was light as investors prepared for the holiday weekend. The Dow managed to hold onto its early gains while the Nasdaq struggled and spent the day in negative territory, though its losses were modest. ECONOMIC NEWS: In the U.S., the MBA mortgage market index rose 5.5% for the week ending November 18. Initial jobless claims rose 18,000 to 251,000 in the week ended November 19, which was just a tick above estimates. Durable goods orders surged 4.8% in October, beating expectations for a 1.5% increase for the month. The FHFA home price index rose 0.6% to 239.2 in September following August's 0.7% increase to 237.9. Markit's manufacturing PMI came in at 53.9 in the flash November reading, slightly above consensus of 53.5. October new home sales of 563,000 were below expectations of 590,000. The University of Michigan consumer sentiment reading climbed 6.6 points to 93.8 in November, after slipping 4 points to 87.2 in October. Crude oil inventories showed a 1.26M barrel draw versus consensus of a 1.0M build. Baker Hughes reported that the rig count is up 5 rigs from last week to 593. The minutes from the last Federal Open Market Committee meeting show some officials favor a rate hike at the central bank's next meeting. "Most participants expressed a view that it could well become appropriate to raise the target range for the federal funds rate relatively soon, so long as incoming data provided some further evidence of continued progress toward the Committee's objectives," the minutes state. In Europe, November's flash Eurozone PMI composite output index rose to 54.1, which is the best reading of 2016 and an 11-month high. COMPANY NEWS: It was tough day for a number of drugmakers following setbacks for potential products that are in development to battle Alzheimer's disease and cancer. Shares of Eli Lilly (LLY) dropped 10.5% after the drugmaker announced that a Phase 3 study showed that solanezumab failed to slow loss of cognitive ability in patients with mild Alzheimer's. Biogen (BIIB), which is developing its own Alzheimer's drug, also slipped nearly 4% following the news. Meanwhile, shares of Juno Therapeutics (JUNO) plunged 24.5% after the company announced that it has voluntarily placed on hold the Phase 2 clinical trial of JCAR015 after two patients suffered cerebral edema earlier this week and subsequently died. Other companies working on "CAR-T" therapies, a new class of oncology drugs that reengineer a patient's own cells to attack the disease, including Kite Pharma (KITE), also ended the trading day lower... Shares of Deere (DE) gained 11% after the maker of large farming machinery topped fourth quarter sales and profit expectations. Additionally, the company expects declining sales of farm machinery to start to ease next year. MAJOR MOVERS: Among the notable gainers was GameStop (GME), which advanced more than 8% after reporting better than expected third quarter earnings per share. Also higher after earnings was Caleres (CAL), which gained 14.2% after beating quarterly expectations. Among the noteworthy losers was Nimble Storage (NMBL), which fell about 16% after the company reported in-line third quarter results but provided fourth quarter guidance that came in below expectations. Also lower was Urban Outfitters (URBN), which dropped 12% after the retailer's third quarter results missed profit and sales expectations. Additionally, HP Inc. (HPQ) slid almost 7% despite posting in-line fourth quarter adjusted earnings per share and better than expected revenue for the quarter. However, steady declines in the company's printing business and a weak outlook for 2017 continue to worry investors. INDEXES: The Dow rose 59.31, or 0.31%, to 19,083.18, the Nasdaq lost 5.67, or 0.11%, to 5,380.68, and the S&P 500 declined 1.78, or 0.08%, to 2,204.72.

LLY

Eli Lilly

$67.98

-8.01 (-10.54%)

BIIB

Biogen

$305.93

-12.18 (-3.83%)

DE

Deere

$102.21

10.2 (11.09%)

JUNO

Juno Therapeutics

$22.57

-7.315 (-24.48%)

KITE

Kite Pharma

$50.95

-0.74 (-1.43%)

GME

GameStop

$25.98

1.87 (7.76%)

CAL

Caleres

$32.30

3.85 (13.53%)

NMBL

Nimble Storage

$7.77

-1.475 (-15.96%)

URBN

Urban Outfitters

$34.31

-4.7 (-12.05%)

HPQ

HP Inc.

$14.83

-1.12 (-7.02%)

  • 23

    Nov

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

  • 09

    Jan

LLY Eli Lilly
$67.98

-8.01 (-10.54%)

11/23/16
MSCO
11/23/16
NO CHANGE
Target $73
MSCO
Equal Weight
Eli Lilly price target lowered to $73 from $88 at Morgan Stanley
Morgan Stanley analyst David Risinger lowered his price target for Eli Lilly to $73 after removing Alzheimer's candidate solanezumab from his model. Following this morning's Phase 3 failure, the analyst keeps an Equal Weight rating on the shares. The next catalyst for Eli Lilly is the FDA's action on Jardiance's label by December 4, Risinger tells investors in a research note. He expects Jardiance to get a CV death reduction indication. The analyst notes that his and consensus 2020 estimates have "significant downside" should the indication not be granted. Lilly is down 11%, or $8.28, to $67.71 in afternoon trading.
11/23/16
COWN
11/23/16
NO CHANGE
Target $85
COWN
Outperform
Eli Lilly price target lowered to $85 from $100 at Cowen
Cowen analyst Steve Scala eliminated solanezumab from his Eli Lilly model which lowered 2018 earnings forecasts to $4.15 from $4.35 and 2019 to $4.75 from $5.30 and a reduction in his price target to $85 from $100. Despite the solanezumab setback, Scala said Outperform rated Eli Lilly has a number of promising new drugs and late-stage agents poised to launch over the next several years that given him confidence in sales and earnings growth prospects.
11/23/16
BMOC
11/23/16
DOWNGRADE
BMOC
Market Perform
Eli Lilly downgraded to Market Perform from Outperform at BMO Capital
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Axovant not impacted by Lilly's solanezumab failure, says JMP Securities
JMP Securities analyst Jason Butler said Axovant Sciences (AXON) is not impacted by Eli Lilly's (LLY) solanezumab. The analyst said solanezumab has a very different mechanism of action, and unlike solanezumab, Axovant's has already prospectively demonstrated statistically significant improvements in cognition and function in a pivotal trial. Butler recommends buying Axovant on weakness and reiterates his Outperform rating and $36 price target.
BIIB Biogen
$305.93

-12.18 (-3.83%)

11/23/16
JEFF
11/23/16
NO CHANGE
Target $310
JEFF
Buy
Biogen selloff may be an overreaction, says Jefferies
Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
11/23/16
MSCO
11/23/16
NO CHANGE
MSCO
Overweight
Morgan Stanley expects big reversal today in Biogen shares
Morgan Stanley Matthew Harrison expects shares of Biogen (BIIB) to end the trading day flat or slightly higher. The stock is currently down $26.61, or 8%, to $291.50 in pre-market trading. With Biogen's aducanumab more potent than Eli Lilly's solanezumab, the Alzheimer's drug still has potential for success, Harrison tells investors in a research note. He points out that Lilly management noted that "the study results, including many secondary clinical endpoints, directionally favored solanezumab." Harrison sees hope in the amyloid hypothesis. The analyst has an Overweight rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
DE Deere
$102.21

10.2 (11.09%)

10/31/16
BARD
10/31/16
UPGRADE
Target $100
BARD
Outperform
Deere upgraded to Outperform at Baird
As reported previously, Baird analyst Mircea Dobre raised his rating on Deere to Outperform from Neutral, noting that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. Dobre reiterated his Outperform rating and raised his price target to $100 from $86 on Deere shares.
11/11/16
DBAB
11/11/16
NO CHANGE
Target $102
DBAB
Buy
Deustche says infrastructure upside not fully priced into Machinery names
Deutsche Bank analyst Nicole DeBlase expects infrastructure stimulus to be more of a 2018 "earnings tailwind" with legislation unlikely until the spring of 2017 at the earliest. She's skeptical that the rally in Machinery stocks can continue for an extended amount of time, but feels only 50% of the total benefit has been priced in, to date. Caterpillar (CAT) is the best way to play a U.S. infrastructure stimulus, DeBlase tells investors in a research note. She raised her price target for the shares to $102 from $95. The analyst also raised her price target for Buy-rated Oshkosh (OSK) to $72 from $65, for Hold-rated Deere (DE) to $95 from $90 and for Sell-rated CNH Industrial (CNHI) to $7.20 from $6.24.
10/31/16
BARD
10/31/16
UPGRADE
BARD
Outperform
Deere upgraded to Outperform from Neutral at Baird
10/31/16
10/31/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Neutral from Underperform at Daiwa. 2. Chevron (CVX) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying that after a decade of relatively flat production, the company is positioned for "strong volume improvement." 3. Fossil (FOSL) upgraded to Mixed from Negative at OTR Global with the firm saying checks indicate the response to Michael Kors (KORS) watches has been strong. 4. ADTRAN (ADTN) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux citing the share pullback over merger concerns of its top customer CenturyLink (CTL). 5. Deere (DE) upgraded to Outperform from Neutral at Baird with analyst Mircea Dobre saying that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JUNO Juno Therapeutics
$22.57

-7.315 (-24.48%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
11/23/16
11/23/16
NO CHANGE

Buy
bluebird bio weakness unwarranted after Juno trial halt, says Janney Capital
As previously reported, Janney Capital analyst Debjit Chattopadhyay said the weakness in bluebird bio (BLUE) is unwarranted on the heels of Juno's (JUNO) second clinical hold for JCAR015. Chattopadhyay notes several key differences between JCAR015 and bluebird's bb2121, including their targets, diseases, vectors, preconditioning regimens and others. He remains a buyer of bluebird ahead of a "potentially watershed ASH for its lentiglobin platform" and keeps a Buy rating on the stock.
11/23/16
JPMS
11/23/16
NO CHANGE
Target $34
JPMS
Neutral
Juno Therapeutics price target lowered to $34 from $39 at JPMorgan
JPMorgan analyst Cory Kasimov lowered his price target for Juno Therapeutics to $34 after the company voluntarily placed the JCAR015 pivotal ROCKET study on clinical hold. The analyst reiterates a Neural rating on the shares.
11/23/16
FBRC
11/23/16
DOWNGRADE
FBRC
Market Perform
Juno Therapeutics downgraded to Market Perform from Outperform at FBR Capital
KITE Kite Pharma
$50.95

-0.74 (-1.43%)

10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
GME GameStop
$25.98

1.87 (7.76%)

11/02/16
PIPR
11/02/16
DOWNGRADE
PIPR
Neutral
GameStop downgraded to Neutral from Overweight at Piper Jaffray
11/11/16
PIPR
11/11/16
NO CHANGE
PIPR
Oct. NPD video game software sales rose 11%, says Piper Jaffray
Piper Jaffray analyst Michael Olson says October NPD video game software sales were up 11% year-over-year due to strong results from incremental launch titles, including Electronic Arts' (EA) Battlefield 1 as well as Take Two's (TTWO) Mafia III, among others. The analyst, however, views the October NPD results as "largely irrelevant" since Activision Blizzard (ATVI), EA and Take-Two already announced December quarter guidance and GameStop (GME) recently announced preliminary October quarter results. He keeps Overweight ratings on all four names.
11/03/16
BARD
11/03/16
NO CHANGE
Target $25
BARD
Outperform
GameStop price target lowered to $25 from $40 at Baird
Baird analyst Colin Sebastian lowered his price target on GameStop to $25 from $40 following its Q3 preannouncement. The analyst said his field checks indicated mixed pre-order levels for key holiday titles through October and he expects promotional activity to drive holiday demand. Sebastian maintained his Buy rating on GameStop shares as his rating is based on the company's long-term diversification strategy and ongoing free cash flow generation.
11/02/16
PIPR
11/02/16
DOWNGRADE
Target $23
PIPR
Neutral
GameStop cut to Neutral on game business erosion at Piper Jaffray
As previously reported, Piper Jaffray analyst Michael Olson, downgraded GameStop to Neutral from Overweight after the company pre-released a quarterly earnings miss and lowered its fiscal year guidance. This quarter will "prove to be a microcosm of the next several years," as the company's core gaming business erosion cannot be offset by growth in its new initiatives, predicted Olson, who lowered his price target on GameStop shares to $23 from $41.
CAL Caleres
$32.30

3.85 (13.53%)

01/27/16
01/27/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Buy at Citi... Brocade (BRCD) initiated with a Neutral at Citi... CBL & Associates (CBL) initiated with an Underperform at Boenning & Scattergood... Caleres (CAL) initiated with a Hold at BB&T... Ciena (CIEN) initiated with a Neutral at Citi... Fitbit (FIT) initiated with a Buy, $35 target at Citi... Genesco (GCO) initiated with a Hold at BB&T... Infinera (INFN) initiated with a Buy at Citi... Nabriva Therapeutics (NBRV) initiated with a Buy at Gabelli... SanDisk (SNDK) initiated with a Buy at Citi... Seagate (STX) initiated with a Sell at Citi... Tanger Factory (SKT) initiated with an Underperform at Boenning & Scattergood... Taubman Centers (TCO) initiated with a Neutral at Boenning & Scattergood... WP Glimcher (WPG) initiated with an Underperform at Boenning & Scattergood... Western Digital (WDC) initiated with a Buy at Citi... Yirendai (YRD) initiated with a Buy at Needham.
02/25/16
BUCK
02/25/16
UPGRADE
BUCK
Buy
Caleres upgraded to Buy from Neutral at Buckingham
05/27/16
05/27/16
UPGRADE
Target $26

Buy
Caleres upgraded to Buy from Hold at BB&T
BB&T analyst Corinna Freedman upgraded Caleres due to valuation following the Q1 report and established a $26 price target on shares.
01/27/16
01/27/16
INITIATION

Hold
Caleres initiated with a Hold at BB&T
NMBL Nimble Storage
$7.77

-1.475 (-15.96%)

11/23/16
MAXM
11/23/16
NO CHANGE
Target $12
MAXM
Buy
Nimble Storage shows multiple signs of turnaround progress, says Maxim
Maxim analyst Nehal Chokshi said multiple metrics, including 5K bookings acceleration and SME bookings acceleration, indicate Nimble Storage's turnaround is progressing, which he believes will become more apparent in next quarter. The company's Lenovo deal and R&D pipeline give him further confidence that Nimble will be a long-term storage player, added Chokshi, who keeps a Buy rating and $12 price target on the shares, which are down about 13% to $8.05 in pre-market trading.
10/03/16
SUSQ
10/03/16
NO CHANGE
Target $12
SUSQ
Positive
Nimble Storage well positioned to gain market share, says Susquehanna
Susquehanna analyst Mehdi Hosseini believes Nimble Storage remains well positioned to continue to gain market share with its dual faceted approach and material operating leverage on the horizon in 2018. Hosseini reiterated his Positive rating and $12 price target on Nimble Storage shares.
09/29/16
WELS
09/29/16
UPGRADE
WELS
Outperform
Nimble Storage upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Maynard Um upgraded Nimble Storage to Outperform saying the risk/reward is favorable at current valuation levels. A "strong pipeline" for Nimble's all-flash array should drive revenue acceleration in FY18 and multiple expansion, Um tells investors in a research note. The analyst raised his price target range for the shares to $10-$11 from $9-$10.
11/23/16
SUSQ
11/23/16
NO CHANGE
Target $12
SUSQ
Positive
Nimble Storage takeover prospects cannot be overlooked, says Susquehanna
Susquehanna analyst Mehdi Hosseini noted Nimble Storage reported relatively in-line Q3 results and guidance. The analyst said that was enough to keep his framework intact as he believes the company is well positioned to continue gaining market share with its Hybrid/All-Flash portfolio. Hosseini also said its prospects as a takeover target for a large player should not be overlooked. Hosseini reiterated his Positive rating and $12 price target on Nimble Storage shares.
URBN Urban Outfitters
$34.31

-4.7 (-12.05%)

11/23/16
JEFF
11/23/16
NO CHANGE
Target $45
JEFF
Buy
Jefferies reiterates Buy on Urban Outfitters after Q3 miss
Jefferies analyst Randal Konik reiterates a Buy rating on Urban Outfitters with a $45 price target following the company's Q3 miss. The analyst remains "encouraged" by the momentum at the Urban Outfitters brand, which he notes is bucking the industry trend with higher store traffic. He sees Anthropologie "finding its way" over the next several quarters.
11/23/16
STFL
11/23/16
NO CHANGE
STFL
Urban Outfitters long-term outlook still positive, says Stifel
After Urban Outfitters reported lower than expected Q3 EPS, Stifel analyst Richard Jaffe says that weakness at the company's Anthrolopolgie unit hindered the company's results. He thinks that Anthrolopologie's offerings continue to be "weak." Jaffe expects the stock to be pressured in the near-term, but he remains upbeat on the company's outlook, partly due to what he sees as its "strong brand equity" and "significant growth opportunities." He keeps a $40 price target and a Buy rating on the shares.
11/23/16
BARD
11/23/16
NO CHANGE
Target $38
BARD
Outperform
Urban Outfitters margin outlook murkier than anticipated, says Baird
Baird analyst Mark Altschwager noted Urban Outfitters reported weaker than expected Q3 results as sluggish apparel demand at Anthropologie weighed on consolidated comps and margins. The analyst said the apparel market remains choppy and the margin picture is murkier than anticipated and recommends investors wait for opportunities to build or add to positions in the low $30's and look to trim positions in the high $30's. Altschwager maintained his Outperform rating on Urban Outfitters shares.
11/23/16
WDLK
11/23/16
DOWNGRADE
Target $32
WDLK
Hold
Wunderlich downgrades Urban Outfitters on 'anemic' Q3 results
Wunderlich analyst Eric Beder downgraded Urban Outfitters to Hold from Buy saying the retailer's "anemic" Q3 results disproved his entire investment thesis. Sales momentum at Free People and Anthropologie continued to weaken and gross margins remained challenged despite easy comparisons, Beder tells investors in a post-earnings research note. He cut his price target for the shares to $32 from $40. Urban Outfitters is down 11%, or $4.14, to $34.87 in pre-market trading.
HPQ HP Inc.
$14.83

-1.12 (-7.02%)

11/23/16
JEFF
11/23/16
DOWNGRADE
Target $16.75
JEFF
Hold
HP Inc. downgraded to Hold from Buy at Jefferies
Jefferies analyst James Kisner downgraded HP Inc. to Hold with a $16.75 price target following the company's Q4 results. The analyst cites valuation and secular challenges for the downgrade.
10/14/16
BMUR
10/14/16
NO CHANGE
Target $18
BMUR
Buy
HP Inc. new business model conservative, says Brean Capital
Brean Capital analyst Ananda Baruah attended the HP, Inc. analyst day and said although it didn't hold any surprises, he believes the company's new long-term business model remains conservative. The analyst said if the company can execute its model its revenue growth will have to be stronger than stated and its guidance must be conservative. Baruah reiterated his Buy rating and $18 price target on HP, Inc. shares.
11/23/16
11/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Salmon citing valuation and his belief that the shares will soon begin to trade based on a potential deal with Viacom (VIA, VIAB). 2. Abercrombie & Fitch (ANF) downgraded to Sell from Hold at Deutsche Bank with analyst Tiffany Kanaga saying the Abercrombie brand turnaround is yet to gain traction. 3. Twitter (TWTR) downgraded to Negative from Mixed at OTR Global. 4. HP Inc. (HPQ) downgraded to Hold from Buy at Jefferies with analyst James Kisner citing valuation and secular challenges for the downgrade. 5. First Solar (FSLR) downgraded to Neutral from Outperform at Macquarie with analyst Gurpreet Gujral citing a lack of catalysts after the company canceled the Series 5 product that was originally scheduled to launch in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/16
MAXM
08/25/16
DOWNGRADE
Target $15
MAXM
Hold
HP Inc. downgraded to Hold on pressured printing margins at Maxim
As previously reported, Maxim analyst Nehal Chokshi downgraded HP Inc. to Hold from Buy and lowered his price target to $15 from $17, saying that his analysis points to sustained printing supplies pricing pressure despite the refresh of its printer hardware. Chokshi added that he expects the company to lower its FY17 earnings guidance at its Securities Analyst Meeting in October.

TODAY'S FREE FLY STORIES

SGMO

Sangamo

19:39
12/05/16
12/05
19:39
12/05/16
19:39
Hot Stocks
Sangamo reports preclinical, manufacturing data on SB-525, says IND on track »

Sangamo BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

, BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

19:38
12/05/16
12/05
19:38
12/05/16
19:38
Hot Stocks
Seattle Genetics, Bristol-Myers: Data supports ADCETRIS, Opdivo combo »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

LGIH

LGI Homes

$32.34

0.45 (1.41%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
LGI Homes reports November home closings up 28.9% y/y »

LGI Homes announced 321…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$116.56

-1.07 (-0.91%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
Celgene reports analysis of three CC-486 studies »

Celgene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BLUE

bluebird bio

$72.15

2.4 (3.44%)

19:35
12/05/16
12/05
19:35
12/05/16
19:35
Hot Stocks
bluebird bio provides updates on HSC gene therapy programs »

bluebird bio provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$49.88

-7.09 (-12.45%)

19:33
12/05/16
12/05
19:33
12/05/16
19:33
Hot Stocks
Agios 'encouraged' by durable clinical activity of AG-120 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$60.25

-0.88 (-1.44%)

19:31
12/05/16
12/05
19:31
12/05/16
19:31
Hot Stocks
Merck: KEYNOTE-087 trial data shows oORR of 69%, CRR of 22.4% »

Merck announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Mar

TWX

Time Warner

$93.34

-0.46 (-0.49%)

, T

AT&T

$38.63

0.02 (0.05%)

19:29
12/05/16
12/05
19:29
12/05/16
19:29
Periodicals
Time Warner 'struggling to expand' HBO Now, NY Post says »

Time Warner (TWX) is…

TWX

Time Warner

$93.34

-0.46 (-0.49%)

T

AT&T

$38.63

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

BP

BP

, REPYY

Repsol

$13.88

0.25 (1.83%)

19:18
12/05/16
12/05
19:18
12/05/16
19:18
Periodicals
BP acquires Repsol stake in Indonesia LNG plant, Reuters says »

BP (BP) has purchased…

BP

BP

REPYY

Repsol

$13.88

0.25 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSUF

Fosun

19:12
12/05/16
12/05
19:12
12/05/16
19:12
Hot Stocks
Liberty Mutual to acquire Fosun subsidiary Ironshore for roughly $3B »

Liberty Mutual Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$49.75

-0.06 (-0.12%)

, YHOO

Yahoo

$40.20

0.13 (0.32%)

18:54
12/05/16
12/05
18:54
12/05/16
18:54
Periodicals
AOL CEO 'cautiously optimistic' Verizon-Yahoo deal will go through, WSJ says »

AOL CEO Tim Armstrong…

VZ

Verizon

$49.75

-0.06 (-0.12%)

YHOO

Yahoo

$40.20

0.13 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 24

    Jan

TUWOY

Tullow Oil

$2.06

0.109 (5.58%)

18:46
12/05/16
12/05
18:46
12/05/16
18:46
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$22.15

0.75 (3.50%)

18:43
12/05/16
12/05
18:43
12/05/16
18:43
Hot Stocks
Breaking Hot Stocks news story on Guaranty Bancorp »

Castle Creek raises stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$20.48

-0.18 (-0.87%)

18:41
12/05/16
12/05
18:41
12/05/16
18:41
Syndicate
Atkore files to sell 8M shares of common stock for holders »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$107.42

-0.8 (-0.74%)

18:38
12/05/16
12/05
18:38
12/05/16
18:38
Hot Stocks
United Technologies CEO: No quid pro quo on taxes in Carrier deal with Trump »

Says Carrier agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPDN

Professional Diversity Network

$9.75

-0.01 (-0.10%)

18:37
12/05/16
12/05
18:37
12/05/16
18:37
Hot Stocks
Breaking Hot Stocks news story on Professional Diversity Network »

North Star cuts passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$5.05

-0.36 (-6.65%)

18:33
12/05/16
12/05
18:33
12/05/16
18:33
Hot Stocks
Breaking Hot Stocks news story on DHX Media »

Luxor Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPHS

Trinity Place

$10.02

0.08 (0.80%)

18:24
12/05/16
12/05
18:24
12/05/16
18:24
Hot Stocks
Trinity Place Holdings, Pacolet Milliken acquire Brooklyn building for $68.8M »

Trinity Place Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$32.46

0.23 (0.71%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Suncor Energy resolves C$1.3B tax dispute with Canada Revenue Agency »

Suncor Energy reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

, CELG

Celgene

$116.56

-1.07 (-0.91%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Acceleron, Celgene report Phase 2 data on luspatercept in beta-thalassemia »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

CELG

Celgene

$116.56

-1.07 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

SNSS

Sunesis

$4.02

0.12 (3.08%)

17:54
12/05/16
12/05
17:54
12/05/16
17:54
Hot Stocks
Sunesis says new VALOR trial data show 'compelling durable survival outcomes' »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$26.02

-0.27 (-1.03%)

, BOBE

Bob Evans

$46.77

1.05 (2.30%)

17:52
12/05/16
12/05
17:52
12/05/16
17:52
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Coupa…

COUP

Coupa Software

$26.02

-0.27 (-1.03%)

BOBE

Bob Evans

$46.77

1.05 (2.30%)

TXMD

TherapeuticsMD

$6.17

0.04 (0.65%)

KMI

Kinder Morgan

$21.46

0.1 (0.47%)

SB

Safe Bulkers

LXRX

Lexicon

$15.64

0.66 (4.41%)

FET

Forum Energy

$23.20

1.15 (5.22%)

RCII

Rent-A-Center

$11.91

0.38 (3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 28

    Feb

  • 06

    Dec

KPTI

Karyopharm

$8.87

-0.41 (-4.42%)

17:47
12/05/16
12/05
17:47
12/05/16
17:47
Hot Stocks
Karyopharm presents updated Phase 1b STOMP data at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BOBE

Bob Evans

$46.77

1.05 (2.30%)

17:47
12/05/16
12/05
17:47
12/05/16
17:47
Hot Stocks
Bob Evans says evaluating potential opportunities for value creation »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

17:46
12/05/16
12/05
17:46
12/05/16
17:46
Hot Stocks
Google posts job listing for 'conservative outreach' manager »

Google has posted a job…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.